ES2989774T3 - Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos - Google Patents
Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos Download PDFInfo
- Publication number
- ES2989774T3 ES2989774T3 ES16815331T ES16815331T ES2989774T3 ES 2989774 T3 ES2989774 T3 ES 2989774T3 ES 16815331 T ES16815331 T ES 16815331T ES 16815331 T ES16815331 T ES 16815331T ES 2989774 T3 ES2989774 T3 ES 2989774T3
- Authority
- ES
- Spain
- Prior art keywords
- aav
- nucleotide sequence
- vector
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100022641 Coagulation factor IX Human genes 0.000 title claims abstract description 246
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 171
- 108010076282 Factor IX Proteins 0.000 title abstract description 210
- 229960004222 factor ix Drugs 0.000 title abstract description 177
- 238000000034 method Methods 0.000 title abstract description 65
- 238000012546 transfer Methods 0.000 title abstract description 11
- 210000000056 organ Anatomy 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 title description 57
- 239000013598 vector Substances 0.000 claims abstract description 181
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 108
- 230000014509 gene expression Effects 0.000 claims abstract description 91
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 71
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 71
- 238000013518 transcription Methods 0.000 claims abstract description 13
- 230000035897 transcription Effects 0.000 claims abstract description 13
- 210000000234 capsid Anatomy 0.000 claims description 136
- 102000040430 polynucleotide Human genes 0.000 claims description 117
- 108091033319 polynucleotide Proteins 0.000 claims description 117
- 239000002157 polynucleotide Substances 0.000 claims description 117
- 102000004169 proteins and genes Human genes 0.000 claims description 110
- 239000002773 nucleotide Substances 0.000 claims description 94
- 125000003729 nucleotide group Chemical group 0.000 claims description 94
- 229960000027 human factor ix Drugs 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 58
- 208000009429 hemophilia B Diseases 0.000 claims description 45
- 101710132601 Capsid protein Proteins 0.000 claims description 38
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 38
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 38
- 101710108545 Viral protein 1 Proteins 0.000 claims description 38
- 239000003623 enhancer Substances 0.000 claims description 38
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 239000013608 rAAV vector Substances 0.000 claims description 31
- 230000002829 reductive effect Effects 0.000 claims description 31
- 210000004185 liver Anatomy 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 13
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 13
- 241000702421 Dependoparvovirus Species 0.000 claims description 12
- 101100172173 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) hcr-1 gene Proteins 0.000 claims description 12
- 230000008488 polyadenylation Effects 0.000 claims description 11
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims description 3
- 102000051631 human SERPINA1 Human genes 0.000 claims description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 3
- 230000003612 virological effect Effects 0.000 abstract description 35
- 239000013603 viral vector Substances 0.000 abstract description 18
- 238000013519 translation Methods 0.000 abstract description 6
- 108091026890 Coding region Proteins 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 2
- 239000013607 AAV vector Substances 0.000 description 148
- 230000000694 effects Effects 0.000 description 103
- 235000018102 proteins Nutrition 0.000 description 92
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 70
- 201000010099 disease Diseases 0.000 description 61
- 108091028043 Nucleic acid sequence Proteins 0.000 description 37
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 230000001225 therapeutic effect Effects 0.000 description 32
- 239000002245 particle Substances 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 101710081079 Minor spike protein H Proteins 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 25
- 238000006467 substitution reaction Methods 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 24
- 238000001802 infusion Methods 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 22
- 108090000565 Capsid Proteins Proteins 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 19
- 102100023321 Ceruloplasmin Human genes 0.000 description 19
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 19
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 19
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 19
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 239000003018 immunosuppressive agent Substances 0.000 description 19
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 18
- -1 AAV) Substances 0.000 description 17
- 208000009292 Hemophilia A Diseases 0.000 description 17
- 241000124008 Mammalia Species 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000008901 benefit Effects 0.000 description 16
- 208000026578 Severe hemophilia B Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000000945 filler Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000028993 immune response Effects 0.000 description 14
- 230000002459 sustained effect Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 13
- 108091062157 Cis-regulatory element Proteins 0.000 description 13
- 208000031220 Hemophilia Diseases 0.000 description 13
- 108091092195 Intron Proteins 0.000 description 13
- 208000032811 Moderate hemophilia B Diseases 0.000 description 13
- 230000002411 adverse Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 12
- 230000023597 hemostasis Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000011285 therapeutic regimen Methods 0.000 description 12
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 11
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 11
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 11
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 11
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 11
- 241000649045 Adeno-associated virus 10 Species 0.000 description 11
- 241000649046 Adeno-associated virus 11 Species 0.000 description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 11
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 11
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 11
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 230000005867 T cell response Effects 0.000 description 9
- 230000002950 deficient Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 239000004475 Arginine Substances 0.000 description 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 8
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 8
- 229940125721 immunosuppressive agent Drugs 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 229940124589 immunosuppressive drug Drugs 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 230000026683 transduction Effects 0.000 description 7
- 102100026735 Coagulation factor VIII Human genes 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 239000002753 trypsin inhibitor Substances 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000001594 aberrant effect Effects 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000009256 replacement therapy Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 235000014393 valine Nutrition 0.000 description 5
- 239000004474 valine Substances 0.000 description 5
- 108020005345 3' Untranslated Regions Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 4
- 201000003542 Factor VIII deficiency Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 208000026567 Mild hemophilia B Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091005461 Nucleic proteins Proteins 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 208000031169 hemorrhagic disease Diseases 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940065638 intron a Drugs 0.000 description 4
- 235000005772 leucine Nutrition 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 208000015294 blood coagulation disease Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000002085 hemarthrosis Diseases 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 235000014705 isoleucine Nutrition 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 238000007449 liver function test Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000000188 diaphragm Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 102000053020 human ApoE Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000013831 Coagulation factor IX Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 101001048057 Dictyostelium discoideum 32 kDa heat shock protein Proteins 0.000 description 1
- 102100025907 Dyslexia-associated protein KIAA0319-like protein Human genes 0.000 description 1
- 101710205593 Dyslexia-associated protein KIAA0319-like protein Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100028652 Gamma-enolase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000979333 Homo sapiens Neurofilament light polypeptide Proteins 0.000 description 1
- 102000016252 Huntingtin Human genes 0.000 description 1
- 108050004784 Huntingtin Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 1
- 101710098224 Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229940105774 coagulation factor ix Drugs 0.000 description 1
- 229940105778 coagulation factor viii Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010013935 factor IX-Padua Proteins 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000010242 retro-orbital bleeding Methods 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562183599P | 2015-06-23 | 2015-06-23 | |
| US201662315453P | 2016-03-30 | 2016-03-30 | |
| US201662338315P | 2016-05-18 | 2016-05-18 | |
| US201662348781P | 2016-06-10 | 2016-06-10 | |
| US201662349572P | 2016-06-13 | 2016-06-13 | |
| PCT/US2016/039075 WO2016210170A1 (en) | 2015-06-23 | 2016-06-23 | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2989774T3 true ES2989774T3 (es) | 2024-11-27 |
Family
ID=57586246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16815331T Active ES2989774T3 (es) | 2015-06-23 | 2016-06-23 | Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US10799566B2 (OSRAM) |
| EP (2) | EP4378487A3 (OSRAM) |
| JP (3) | JP6831779B2 (OSRAM) |
| KR (2) | KR102178322B1 (OSRAM) |
| CN (1) | CN108138159A (OSRAM) |
| AU (2) | AU2016282781A1 (OSRAM) |
| CA (1) | CA2990193A1 (OSRAM) |
| CO (1) | CO2018000134A2 (OSRAM) |
| DK (1) | DK3313991T3 (OSRAM) |
| ES (1) | ES2989774T3 (OSRAM) |
| FI (2) | FI3313991T3 (OSRAM) |
| FR (1) | FR25C1002I1 (OSRAM) |
| HR (1) | HRP20241180T1 (OSRAM) |
| HU (2) | HUE068603T2 (OSRAM) |
| IL (2) | IL309741A (OSRAM) |
| MX (2) | MX390848B (OSRAM) |
| NO (1) | NO2025003I1 (OSRAM) |
| PE (1) | PE20180675A1 (OSRAM) |
| PH (1) | PH12017502424A1 (OSRAM) |
| PL (1) | PL3313991T3 (OSRAM) |
| PT (1) | PT3313991T (OSRAM) |
| SA (1) | SA517390590B1 (OSRAM) |
| SG (1) | SG10202100131WA (OSRAM) |
| SI (1) | SI3313991T1 (OSRAM) |
| WO (1) | WO2016210170A1 (OSRAM) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2428218T3 (es) | 2005-04-07 | 2013-11-06 | The Trustees Of The University Of Pennsylvania | Cápsides de AAV rh48 modificadas, composiciones que las contienen y usos de las mismas |
| ES2985035T3 (es) | 2008-09-15 | 2024-11-04 | Uniqure Biopharma B V | Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción |
| JP6373763B2 (ja) * | 2012-02-17 | 2018-08-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
| MX2016001044A (es) | 2013-07-22 | 2016-09-09 | The Children's Hospital Of Philadelphia | Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos. |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| PE20180675A1 (es) * | 2015-06-23 | 2018-04-19 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos |
| EP4667565A2 (en) | 2016-10-20 | 2025-12-24 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of fabry disease |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| CN110770346B (zh) * | 2017-03-15 | 2024-01-12 | 北卡罗来纳-查佩尔山大学 | 多倍体腺相关病毒载体及其制备和使用方法 |
| AR112057A1 (es) * | 2017-05-22 | 2019-09-18 | Baxalta Inc | Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b |
| MX2019014379A (es) | 2017-05-31 | 2020-01-23 | Univ North Carolina Chapel Hill | Casetes de expresion optimizados del gen del factor de coagulacion ix humano y su uso. |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| PL3652326T3 (pl) | 2017-07-10 | 2025-02-24 | Uniqure Ip B.V. | Środki i sposoby terapii genowej aav u ludzi |
| EA202091509A1 (ru) | 2017-12-19 | 2020-09-22 | Акуос, Инк. | Aav-опосредованная доставка терапевтических антител во внутреннее ухо |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| KR20210043574A (ko) | 2018-07-09 | 2021-04-21 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 푸소좀 조성물 및 이의 용도 |
| AU2018434176A1 (en) * | 2018-07-27 | 2021-01-28 | Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh | Improved concepts for the treatment of genetic disorders with high-capacity plal-generated gold nanoparticles |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| SG11202101560QA (en) * | 2018-08-20 | 2021-03-30 | Ucl Business Ltd | Factor ix encoding nucleotides |
| GB2576508A (en) * | 2018-08-20 | 2020-02-26 | Ucl Business Plc | Factor IX encoding nucleotides |
| WO2020041773A1 (en) * | 2018-08-24 | 2020-02-27 | Spark Therapeutics, Inc. | Optimized promoter sequences, intron-free expression constructs and methods of use |
| AU2019346655B2 (en) | 2018-09-28 | 2025-03-13 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| MX2021004277A (es) | 2018-10-18 | 2021-09-08 | Intellia Therapeutics Inc | Composiciones y metodos para expresar el factor ix. |
| KR20210090619A (ko) * | 2018-11-09 | 2021-07-20 | 제너레이션 바이오 컴퍼니 | 대칭인 변형된 역말단반복을 포함하는 변형된 폐쇄형 DNA(ceDNA) |
| KR20210112337A (ko) * | 2019-01-04 | 2021-09-14 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| US11596671B2 (en) | 2019-02-01 | 2023-03-07 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression |
| AU2019428629A1 (en) * | 2019-02-06 | 2021-01-28 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
| CN110205297A (zh) * | 2019-05-15 | 2019-09-06 | 华北理工大学 | 一种重组脂肪干细胞及其重组方法 |
| CN114302968A (zh) * | 2019-08-29 | 2022-04-08 | 美国西门子医学诊断股份有限公司 | 用于检测aav脱落的试剂和方法 |
| CN111647625A (zh) * | 2019-12-25 | 2020-09-11 | 深圳三智医学科技有限公司 | 一种提高人凝血因子ix表达水平的方法 |
| CN115667530A (zh) * | 2020-03-24 | 2023-01-31 | 世代生物公司 | 非病毒dna载体和其用于表达因子ix治疗剂的用途 |
| AU2021251175A1 (en) * | 2020-04-07 | 2022-09-22 | The Curators Of The University Of Missouri | CpG-free ITRs for AAV gene therapy |
| CN113817759B (zh) * | 2020-07-10 | 2023-06-02 | 南京吉迈生物技术有限公司 | 修饰的因子ix、组合物、方法及其在基因治疗中的应用 |
| MX2023005218A (es) | 2020-11-03 | 2023-05-16 | Pfizer | Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico. |
| PH12023551518A1 (en) | 2020-12-01 | 2024-05-13 | Akouos Inc | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| US20240052322A1 (en) | 2020-12-15 | 2024-02-15 | Pfizer Inc. | HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins |
| JP2024503234A (ja) | 2020-12-23 | 2024-01-25 | ファイザー・インク | 親和性クロマトグラフィーによるａａｖベクターの精製方法 |
| TW202246505A (zh) * | 2021-03-05 | 2022-12-01 | 俄羅斯聯邦商亞那拜恩有限公司 | 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途 |
| WO2022208342A1 (en) | 2021-04-01 | 2022-10-06 | Pfizer Inc. | Pharmaceutical compositions containing adeno-associated viral vector |
| EP4079860A1 (en) * | 2021-04-23 | 2022-10-26 | uniQure biopharma B.V. | Methods and means for the prevention and/or treatment of joint damage in hemophilia |
| EP4329820A1 (en) | 2021-04-26 | 2024-03-06 | Alexion Pharma International Operations Limited | Adeno-associated viral vector capsids with improved tissue tropism |
| WO2022235614A2 (en) * | 2021-05-04 | 2022-11-10 | Regenxbio Inc. | Novel aav vectors and methods and uses thereof |
| KR20240023638A (ko) | 2021-06-22 | 2024-02-22 | 화이자 인코포레이티드 | 곤충 세포에서의 아데노-연관 바이러스 벡터의 생산 |
| AU2022298827A1 (en) * | 2021-06-23 | 2024-02-08 | Frontera Therapeutics, Inc. | Composition and method for treating hemophilia b |
| CN118660710A (zh) | 2021-10-20 | 2024-09-17 | 罗切斯特大学 | 用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞 |
| US20230149563A1 (en) * | 2021-10-27 | 2023-05-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
| WO2023081633A1 (en) | 2021-11-02 | 2023-05-11 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
| EP4198134A1 (en) * | 2021-12-16 | 2023-06-21 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
| CN118460618A (zh) * | 2022-04-19 | 2024-08-09 | 康霖生物科技（杭州）有限公司 | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体 |
| WO2024003687A1 (en) | 2022-06-28 | 2024-01-04 | Pfizer Inc. | Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy |
| WO2024038365A1 (en) | 2022-08-16 | 2024-02-22 | Pfizer Inc. | Methods for purification of aav vectors by anion exchange chromatography |
| TW202426479A (zh) * | 2022-10-10 | 2024-07-01 | 美商星火治療公司 | Apoe基因療法 |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| EP4658294A2 (en) | 2023-02-02 | 2025-12-10 | University of Rochester | Competitive replacement of glial cells |
| WO2025090427A1 (en) | 2023-10-23 | 2025-05-01 | University Of Rochester | Glial-targeted relief of hyperexcitability in neurodegenerative diseases |
| WO2025143742A1 (ko) * | 2023-12-26 | 2025-07-03 | 삼성바이오에피스 주식회사 | 혈액응고인자 IX를 암호화하는 코돈-최적화된 폴리뉴클레오티드 및 이를 포함하는 rAAV 생산용 플라스미드 |
| WO2025250457A1 (en) | 2024-05-28 | 2025-12-04 | University Of Rochester | Enhanced brain transduction by gene therapeutics |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| WO1998010088A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| US7351813B2 (en) * | 2000-06-20 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Liver-specific gene expression cassettes, and methods of use |
| JP2004532039A (ja) | 2001-03-26 | 2004-10-21 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | ヘルパー依存性アデノウイルスベクター系およびその系の使用方法 |
| US20080220015A1 (en) | 2001-08-03 | 2008-09-11 | Nokad, S.A. | Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal trangenesis and in functional inactivation of endogenous proteins |
| ATE317916T1 (de) | 2001-11-13 | 2006-03-15 | Univ Pennsylvania | Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode |
| EP1453547B1 (en) | 2001-12-17 | 2016-09-21 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
| US20040028654A1 (en) | 2002-03-22 | 2004-02-12 | Board Of Regents, The University Of Texas System | Protamine-adenoviral vector complexes and methods of use |
| NZ536274A (en) | 2002-05-01 | 2008-04-30 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
| WO2005037226A2 (en) * | 2003-10-17 | 2005-04-28 | Georgia Tech Research Corporation | Genetically engineered enteroendocrine cells for treating glucose-related metabolic disorders |
| ES2436741T3 (es) | 2004-09-22 | 2014-01-07 | St. Jude Children's Research Hospital | Expresión mejorada de Factor IX en vectores de terapia génica |
| DE602005015994D1 (de) | 2004-09-29 | 2009-09-24 | Childrens Memorial Hospital | siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN |
| ES2428218T3 (es) | 2005-04-07 | 2013-11-06 | The Trustees Of The University Of Pennsylvania | Cápsides de AAV rh48 modificadas, composiciones que las contienen y usos de las mismas |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US20090317417A1 (en) | 2006-04-28 | 2009-12-24 | The Trustees Of The University Of Pennsylvania | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof |
| CN101511373B (zh) * | 2006-06-19 | 2015-12-09 | 阿斯克肋匹奥生物制药公司 | 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体 |
| DK2282764T3 (da) | 2008-04-22 | 2019-10-14 | Vib Vzw | Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf |
| ES2985035T3 (es) | 2008-09-15 | 2024-11-04 | Uniqure Biopharma B V | Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción |
| GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| CA2770762A1 (en) * | 2009-08-18 | 2011-02-24 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| SG10201800541SA (en) | 2010-04-23 | 2018-03-28 | Univ Florida | Raav-guanylate cyclase compositions and methods for treating leber's congenital amaurosis-1 (lca1) |
| DK2826860T3 (en) | 2010-04-23 | 2018-12-03 | Univ Massachusetts | CNS targeting AAV vectors and methods for their use |
| KR101853405B1 (ko) | 2010-10-20 | 2018-05-02 | 주식회사 티움바이오 | 인자 ｉｘ 활성을 갖는 융합 단백질 |
| US10640785B2 (en) | 2011-11-22 | 2020-05-05 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
| WO2013078316A1 (en) * | 2011-11-23 | 2013-05-30 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| EA201491388A1 (ru) | 2012-02-15 | 2015-01-30 | Байоджен Айдек Ма Инк. | Рекомбинантные белки фактора viii |
| JP6373763B2 (ja) | 2012-02-17 | 2018-08-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
| ES2862912T3 (es) | 2012-04-18 | 2021-10-08 | Childrens Hospital Philadelphia | Composición y procedimientos para la transferencia genética de alta eficiencia utilizando variantes de cápside de VAA |
| AU2013281328B2 (en) * | 2012-06-27 | 2017-11-23 | Meiragtx Uk Ii Limited | Combination for treating an inflammatory disorder |
| GB201213117D0 (en) | 2012-07-24 | 2012-09-05 | Ucl Business Plc | Transgene expression |
| US10398787B2 (en) | 2012-10-26 | 2019-09-03 | Vrije Universiteit Brussel | Vectors for liver-directed gene therapy of hemophilia and methods and use thereof |
| US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
| US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| KR102445330B1 (ko) | 2013-07-12 | 2022-09-19 | 더 칠드런스 호스피탈 오브 필라델피아 | Ａａｖ 벡터 및 항―ａａｖ （아데노-관련 바이러스） 중화 항체에 대한 검정 |
| MX2016001044A (es) * | 2013-07-22 | 2016-09-09 | The Children's Hospital Of Philadelphia | Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos. |
| NL2012981B1 (en) * | 2014-06-11 | 2017-01-17 | Heineken Supply Chain Bv | Beverage dispensing system, beverage container and pressurizing system for use in a beverage dispensing system or container. |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| CA2979495A1 (en) | 2015-03-17 | 2016-09-22 | Vrije Universiteit Brussel | Optimized liver-specific expression systems for fviii and fix |
| PE20180675A1 (es) * | 2015-06-23 | 2018-04-19 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| WO2017180861A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsulvania | Gene therapy for treating hemophilia b |
-
2016
- 2016-06-23 PE PE2017002835A patent/PE20180675A1/es unknown
- 2016-06-23 IL IL309741A patent/IL309741A/en unknown
- 2016-06-23 PT PT168153310T patent/PT3313991T/pt unknown
- 2016-06-23 WO PCT/US2016/039075 patent/WO2016210170A1/en not_active Ceased
- 2016-06-23 EP EP24165196.7A patent/EP4378487A3/en active Pending
- 2016-06-23 PL PL16815331.0T patent/PL3313991T3/pl unknown
- 2016-06-23 MX MX2018000307A patent/MX390848B/es unknown
- 2016-06-23 ES ES16815331T patent/ES2989774T3/es active Active
- 2016-06-23 HU HUE16815331A patent/HUE068603T2/hu unknown
- 2016-06-23 KR KR1020187002040A patent/KR102178322B1/ko active Active
- 2016-06-23 SI SI201631854T patent/SI3313991T1/sl unknown
- 2016-06-23 FI FIEP16815331.0T patent/FI3313991T3/fi active
- 2016-06-23 EP EP16815331.0A patent/EP3313991B1/en active Active
- 2016-06-23 CN CN201680043108.6A patent/CN108138159A/zh active Pending
- 2016-06-23 US US15/191,357 patent/US10799566B2/en active Active
- 2016-06-23 SG SG10202100131WA patent/SG10202100131WA/en unknown
- 2016-06-23 AU AU2016282781A patent/AU2016282781A1/en not_active Abandoned
- 2016-06-23 JP JP2017518931A patent/JP6831779B2/ja active Active
- 2016-06-23 KR KR1020207032060A patent/KR102415896B1/ko active Active
- 2016-06-23 DK DK16815331.0T patent/DK3313991T3/da active
- 2016-06-23 IL IL256517A patent/IL256517B2/en unknown
- 2016-06-23 HR HRP20241180TT patent/HRP20241180T1/hr unknown
- 2016-06-23 CA CA2990193A patent/CA2990193A1/en active Pending
-
2017
- 2017-12-21 SA SA517390590A patent/SA517390590B1/ar unknown
- 2017-12-22 PH PH12017502424A patent/PH12017502424A1/en unknown
-
2018
- 2018-01-08 MX MX2022003116A patent/MX2022003116A/es unknown
- 2018-01-09 CO CONC2018/0000134A patent/CO2018000134A2/es unknown
-
2019
- 2019-12-09 US US16/707,984 patent/US20200129598A1/en not_active Abandoned
-
2020
- 2020-09-08 US US17/014,782 patent/US11110153B2/en active Active
-
2021
- 2021-01-29 JP JP2021012811A patent/JP7361737B2/ja active Active
- 2021-07-12 US US17/305,649 patent/US11491213B2/en active Active
-
2022
- 2022-10-28 US US18/050,982 patent/US11896652B2/en active Active
- 2022-11-09 AU AU2022268345A patent/AU2022268345B2/en active Active
-
2023
- 2023-10-03 JP JP2023171763A patent/JP2024009857A/ja active Pending
- 2023-12-19 US US18/389,662 patent/US20240131126A1/en active Pending
-
2025
- 2025-01-03 FI FIC20250001C patent/FIC20250001I1/fi unknown
- 2025-01-07 NO NO2025003C patent/NO2025003I1/no unknown
- 2025-01-07 HU HUS2500003C patent/HUS2500003I1/hu unknown
- 2025-01-09 FR FR25C1002C patent/FR25C1002I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2989774T3 (es) | Factor IX modificado, y composiciones, métodos y utilizaciones para la transferencia génica a células, órganos y tejidos | |
| JP7607007B2 (ja) | 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法 | |
| ES2752191T3 (es) | Composiciones y métodos con vectores de AAV para la transferencia de genes a células, órganos y tejidos | |
| US20180244727A1 (en) | Capsid-modified raav vector compositions having improved transduction efficiencies, and methods of use | |
| TW202216244A (zh) | 有用於治療夏馬杜三氏病之組成物 | |
| US20240207370A1 (en) | Gene therapy for bcaa modulation in maple syrup urine disease (msud) | |
| WO2023147584A2 (en) | Compositions and methods for treating sialidosis | |
| CN115948408A (zh) | 改进的人凝血因子viii基因表达盒及其应用 | |
| BR112017027956B1 (pt) | Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica | |
| RU2837753C2 (ru) | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани | |
| HK1252351B (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| BR112016001210B1 (pt) | Partículas de aav recombinates, e composição farmacêutica | |
| HK1223849B (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |